Joakim Lundeberg

Biography
Professor Joakim Lundeberg works at the Department of Gene Technology, part of the School of Engineering Sciences in Chemistry, Biotechnology, and Health, KTH Royal Institute of Technology, and has competence in molecular technology development, in the fields of spatial omics with applications in both medicine and environment. Applications cover, for example, cancer, neurology and human development. His research group has been located since May 2010 at the Science for Life Laboratory (SciLifeLab). Prof Lundeberg previously headed the National Genomics Infrastructure (NGI) platform, one of the major academic sequencing sites in Europe.Lundeberg has over 15 patent and patent applications and has established several spin-off companies based on his research.

Judy Faulkner

Biography
Judy Faulkner, founder and CEO of Epic Systems, has significantly impacted precision medicine by pioneering the integration of genomic data into electronic health records, notably through Epics Aura platform, which enables tailored treatment strategies based on individual genetic profiles. Under her leadership, the Cosmos initiative has facilitated the aggregation of extensive de-identified patient data, substantially advancing clinical research and informed medical decision-making. Additionally, by embedding advanced AI technologies into Epic's systems, she has streamlined clinical workflows, aiding healthcare providers in documentation and patient communication. Epics extensive global presence, managing hundreds of millions of patient records, reflects Faulkner's profound influence on the healthcare landscape, further highlighted by her philanthropic commitment to reducing health disparities and improving healthcare accessibility.

Alexis C. Komor

Biography
Alexis C. Komor is a pioneering genomeediting researcher who codeveloped the first CRISPR base editors with David Liu at the Broad Institute. Her work established base editing as a new class of genome engineering tools that enable precise singlenucleotide changes in DNA without doublestrand breaks, laying the foundation for correcting diseasecausing point mutations with high precision. She continues to lead efforts to translate these innovations into direct in vivo therapeutics, including strategies to deliver base editors via mRNA and other nucleicacid platforms to repair genes within patients cells. As her work established the scientific foundation of Beam Therapeutics, Komor has helped drive the clinical development of base editing, underscoring the broad impact of her work on programmable gene editing and precision medicine. Her groundbreaking contributions are influencing a new generation of in vivo RNA and genebased therapies (spanning mRNA, siRNA, and antisense oligonucleotide modalities) and inspiring novel smallmolecule approaches to treat genetic diseases.

---

Talk
Development and Characterization of Precision Genome Editing Tools
Base editors facilitate the introduction of point mutations into the genome of live cells with high efficiencies and precision via targeted nucleobase chemistry. In this talk I will describe my lab's efforts to develop new base editing methodologies and their application to correcting disease-causing mutations.

Catriona Jamieson

Biography
Catriona Jamieson is a leading physician scientist who has specialized in myeloproliferative neoplasms (MPNs) and leukemia. She discovered missplicing, RNA hyperediting, and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. These discoveries have helped to shed light on the underlying mechanisms of cancer and have opened up new avenues for targeted therapies. Dr. Jamieson's contributions to the field of precision medicine include her pivotal role in the rescue and development of the JAK inhibitor fedratinib for the treatment of myelofibrosis. Additionally, she is known for her unwavering dedication to advancing innovative therapies and her outstanding leadership as the director of the Sanford Stem Cell Institute at UCSD and as a co-founder of Impact Biosciences and Aspera Biomedicines.